Recommendations of the Spanish Society of Cardiorespiratory Rehabilitation on pulmonary rehabilitation programmes in patients with chronic obstructive pulmonary disease;Recomendaciones sobre programas de rehabilitación pulmonar en pacientes con enfermedad pulmonar obstructiva crónica de la Sociedad de Rehabilitación Cardiorrespiratoria

Rehabilitacion

Volumn 50, Issue 4, 2016, Pages 233-262

  Marco, E ^a   Coll Artes R ^b   Marin M ^c   Coll Fernandez R ^d   Pascual, M T ^b   Resa, J ^e   Munoz L ^f   Romero, M ^g   Burnham, P M ^c   Ciria M ^h  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Hospital Comarcal de L'Alt Penedes   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h HOSPITAL DEL MAR   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Evaluation; Physical exercise; Pulmonary rehabilitation

Indexed keywords

EID: 85003481230     PISSN: 00487120     EISSN: 15783278     Source Type: Journal    
DOI: 10.1016/j.rh.2016.04.004     Document Type: Article

References (172)

1. 1 Estrategia en EPOC del Sistema Nacional de Salud. Plan de Calidad para el Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Política Social; 2009.
2. 2 Lacasse, Y., Wong, E., Guyatt, G.H., King, D., Cook, D.J., Goldstein, R.S., Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 348 (1996), 115–119.
3. 3 Ries, A.L., Bauldoff, G.S., Casaburi, R., Mahler, D.A., Rochester, C.L., Herrerías, C., Pulmonary rehabilitation. Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 131 (2007), 4S–42S.
4. 4 McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015; CD003793. doi: 10.1002/14651858.CD003793.pub3.
5. 5 Troosters, T., Casaburi, R., Gosselink, R., Decramer, M., Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005), 19–38.
6. 6 Spruit, M.A., Singh, S.J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., et al. An Official American Thoracic Society/European Respiratory Society Statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188 (2013), e13–e64 Erratum in: Am J Respir Crit Care Med. 2014;189:1570.
7. 7 Marciniuk, D.D., Brooks, D., Butcher, S., Debigare, R., Dechman, G., Ford, G., et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease-practical issues: A Canadian Thoracic Society clinical practice guideline. Can Respir J 17 (2010), 159–168.
8. 8 Peces-Barba, G., Barberà, J.A., Agustí, A., Casanova, C., Casas, A., Izquierdo, J.L., et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 44 (2008), 271–281.
9. 9 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 [consultado 30 Sep 2015]. Disponible en: http://www.goldcopd.org/.
10. 10 Miravitlles, M., Soler-Cataluña, J.J., Calle, M., Molina, J., Almagro, P., Quintano, J.A., et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 50 Suppl 1 (2014), 1–16.
11. 11 Miranda, G., Gómez, A., Pleguezuelos, E., Capellas, L., Rehabilitación respiratoria en España. Rehabilitación (Madr) 45 (2011), 247–255.
12. 12 Güell, M.R., de Lucas, P., Gáldiz, J.B., Montemayor, T., Rodríguez González-Moro, J.M., Gorostiza, A., et al. Home vs hospital-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a Spanish multicenter trial. Arch Bronconeumol 44 (2008), 512–518.
13. 13 Maltais, F., Bourbeau, J., Shapiro, S., Lacasse, Y., Perrault, H., Baltzan, M., et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 149 (2008), 869–878.
14. 14 Sewell, L., Singh, S.J., Williams, J.E., Collier, R., Morgan, M.D., How long should outpatient pulmonary rehabilitation be? A randomised controlled trial of 4 weeks versus 7 weeks. Thorax 61 (2006), 767–771.
15. 15 Güell, R., Casan, P., Belda, J., Sangenis, M., Morante, F., Guyatt, G.H., et al. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest 117 (2000), 976–983.
16. 16 Yorke J, Rochnia N, Walters S, Dugdill L, Vestbo J, Calverley P. Maintenance rehabilitation for chronic obstructive pulmonary disease (Protocol). Cochrane Database Syst Rev. 2010; CD008837. doi: 10.1002/14651858. CD008837.
17. 17 Linneberg, A., Rasmussen, M., Buch, T.F., Wester, A., Malm, L., Fannikke, G., et al. A randomised study of the effects of supplemental exercise sessions after a 7-week chronic obstructive pulmonary disease rehabilitation program. Clin Respir J 6 (2012), 112–119.
18. 18 Compte L, Macián V, Blanco M, Rodríguez M. Volúmenes pulmonares. En: Puente-Maestu L, editor. Manual SEPAR de Procedimientos.Madrid: Luzán 5; 2013. pg. 37-66.
19. 19 Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., Casaburi, R., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005), 948–968.
20. 20 Rabe, K.F., Improving dyspnea in chronic obstructive pulmonary disease. Optimal treatment strategies. Proc Am Thorac Soc 3 (2006), 270–275.
21. 21 Nishimura, K., Izumi, T., Tsukino, M., Oga, T., Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 (2002), 1434–1440.
22. 22 Mador, M.J., Rodis, A., Magalang, U.J., Reproducibility of Borg Scale measurements of dyspnea during exercise in patients with COPD. Chest 107 (1995), 1590–1597.
23. 23 Mahler, D.A., Wells, C.K., Evaluation of clinical methods for rating dyspnea. Chest 93 (1988), 580–586.
24. 24 Mahler, D.A., Weinberg, D.H., Wells, C.K., Feinstein, A.R., The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984), 751–758.
25. 25 Witek, T.J., Mahler, D.A., Minimal important difference of the transition dyspnea index in a multinational clinical trial. Eur Respir J 21 (2003), 267–272.
26. 26 Guyatt, G.H., Berman, L.B., Towsend, M., Pugsley, S.O., Chambers, L.W., A measure of quality of life for clinical trials in chronic lung disease. Thorax 42 (1987), 773–778.
27. 27 Lareau, S.C., Meek, P.M., Roos, P.J., Development and testing of the modified version of the pulmonary functional status and dyspnea questionnaire (PFSDQ-M). Heart Lung 27 (1998), 159–168.
28. 28 Migliore Norweg, A.M., Whiteson, J., Demetis, S., Rey, M., A new functional status outcome measure of dyspnea and anxiety for adults with lung disease: The dyspnea management questionnaire. J Cardiopulm Rehabil 26 (2006), 395–404.
29. 29 Clinical exercise testing with reference to lung diseases: Indications, standardization, and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. Eur Respir J 10 (1997), 2662–2689.
30. 30 Solway, S., Brooks, D., Lacasse, Y., Thomas, S., A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119 (2001), 256–270.
31. 31 ATS Committee on Proficiency for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002), 111–117.
32. 32 Celli, B.R., Cote, C.G., Marin, J.M., Casanova, C., Montes de Oca, M., Méndez, R.A., et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004), 1005–1012.
33. 33 Singh, S.J., Morgan, M.D., Hardman, A.E., Rowe, C., Bardsley, P.A., Comparison of oxygen uptake during a conventional treadmill test and shuttle walking test in chronic airflow limitation. Eur Respir J 7 (1994), 2016–2020.
34. 34 Eaton, T., Young, P., Nicol, K., Kolbe, J., The endurance shuttle walking test: A responsive measure in pulmonary rehabilitation for COPD patients. Chron Respir Dis 3 (2006), 3–9.
35. 35 Annegarn, J., Meijer, K., Passos, V.L., Stute, K., Wiechert, J., Savelberg, H.H., et al. Problematic activities of daily life are weakly associated with clinical characteristics in COPD. J Am Med Dir Assoc 13 (2012), 284–290.
36. 36 Divo, M., Pinto-Plata, V., Role of exercise in testing and in therapy of COPD. Med Clin North Am 96 (2012), 753–766.
37. 37 Seymour, J.M., Spruit, M.A., Hopkinson, N.S., Natanek, S.A., Man, W.D., Jackson, A., et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 36 (2010), 81–88.
38. 38 Hopkinson, N.S., Tennant, R.C., Dayer, M.J., Swallow, E.B., Hansel, T.T., Moxham, J., et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res, 8, 2007, 25.
39. 39 Gosselink, R., Troosters, T., Decramer, M., Distribution of muscle weakness in patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil 20 (2000), 353–360.
40. 40 Vilaró, J., Ramírez-Sarmiento, A., Martínez-Llorens, J.M., Mendoza, T., Álvarez, M., Sánchez-Cayado, N., et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 104 (2010), 1896–1902.
41. 41 Marquis, K., Debigaré, R., Lacasse, Y., LeBlanc, P., Jobin, J., Carrier, G., et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002), 809–813.
42. 42 Swallow, E.B., Reyes, D., Hopkinson, N.S., Man, W.D., Porcher, R., Cetti, E.S., et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62 (2007), 115–120.
43. 43 Maltais, F., Decramer, M., Casaburi, R., Barreiro, E., Burelle, Y., Debigaré, R., et al. An official American Thoracic Society/European Respiratory Society statement: Update on limb muscle dysfunction in COPD. Am J Respir Crit Care 189 (2014), e15–e62.
44. 44 Mathur, S., Makrides, L., Hernández, P., Test-retest reliability of isometric and isokinetic torque in patients with chronic obstructive pulmonary disease. Physiother Can 56 (2004), 94–101.
45. 45 Black, L.F., Hyatt, R.E., Maximal respiratory pressures: Normal values and relationship to age and sex. Am Rev Respir Dis, 99, 1969 696-102.
46. a ed., 2008, Editorial Médica Internacional, Bogotá, 232–247.
47. 47 Gea, J., Martínez-Llorens, J.M., Barreiro, E., Nutritional abnormalities in chronic obstructive pulmonary disease. Med Clin (Barc) 143 (2014), 78–84.
48. 48 World Health Organization (WHO). BMI classification [consultado Jun 2015]. Disponible en: http://apps.who.int/bmi/index.jsp?introPage = intro_3.html.
49. 49 Coin, A., Sergi, G., Minicuci, N., Giannini, S., Barbiero, E., Manzato, E., et al. Fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20-80 year-old italian population. Clin Nutr 27 (2008), 87–94.
50. 50 Cáceres, D.I., Messaggi-Sartor, M., Rodríguez, D.A., Escalada, F., Gea, J., Orozco-Levi, M., et al. Variability in bioelectrical impedance assessment of body composition depending on measurement conditions: Influence of fast and rest. Nutr Hospital 30 (2014), 1359–1365.
51. 51 WHO study group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group. Technical Report Series 843. Geneva: WHO; 1994. (ISBN 92-4-120843-0).
52. 52 Nguyen, N.D., Pongchaiyakul, C., Center, J.R., Eismsn, J.A., Nguyen, T.V., Identification of high-risk individuals for hip fracture: A 14-year prospective study. J Bone Miner Res 20 (2005), 1921–1928.
53. 53 Office of the Surgeon General (US). Bone health and osteoporosis: A report of the Surgeon General. Rockville (MD); Office of the Surgeon General (US), 2004 [consultado Oct 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK45513/.
54. 54 Sin, D.D., Man, J.P., Man, S.F., The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114 (2003), 10–14.
55. 55 Reid, I.R., Glucocorticoid-induced osteoporosis: Assessment and treatment. J Clin Densitom 1 (1998), 65–73.
56. 56 Canalis, E., Mazziotti, G., Giustina, A., Bilezikian, J.P., Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 18 (2007), 1319–1328.
57. 57 Dalle Carbonare, L., Bertoldo, F., Valenti, M.T., Zenari, S., Zanatta, M., Sella, S., et al. Histomorphometric análisis of glucocorticoid-induced osteoporosis. Micron 36 (2005), 645–652.
58. 58 Verstraeten, A., Dequeker, J., Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Effect of low dose corticosteroids. Ann Rheum Dis 45 (1986), 852–857.
59. 59 Van Staa, T.P., Leufkens, H.G., Cooper, C., The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 13 (2002), 777–787.
60. 60 Drummond, M.B., Dasenbrook, E.C., Pitz, M.W., Murphy, D.J., Fan, E., Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 300 (2008), 2407–2416.
61. 61 Loke, Y.K., Cavallazzi, R., Singh, S., Risk of fractures with inhaled corticosteroids in COPD: Systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66 (2011), 699–708.
62. 62 De Laet, C.E., van der Klift, M., Hofman, A., Pols, H.A., Osteoporosis in men and women: A story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17 (2002), 2231–2236.
63. 63 Kanis, J.A., Johnell, O., Oden, A., Johansson, H., McCloskey, E., FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19 (2008), 385–397.
64. 64 Kanis, J.A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 (2004), 375–382.
65. 65 Kanis, J.A., Johnell, O., Oden, A., Borgstrom, F., Zethraeus, N., de Laet, C., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15 (2004), 20–26.
66. 66 Sornay-Rendu, E., Munoz, F., Garnero, P., Duboeuf, F., Delmas, P.D., Identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Miner Res 20 (2005), 1813–1819.
67. 67 Bauer, D.C., Black, D.M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19 (2004), 1250–1258.
68. 68 Eastell, R., Barton, I., Hannon, R.A., Chines, A., Garnero, P., Delmas, P.D., Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003), 1051–1056.
69. 69 Hochberg, M.C., Greenspan, S., Wasnich, R.D., Miller, P., Thompson, D.E., Ross, P.D., Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002), 1586–1592.
70. 70 Delmas, P.D., Munoz, F., Black, D.M., Cosman, F., Boonen, S., Watts, N.B., et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Min Res 24 (2009), 1544–1551.
71. 71 Eastell, R., Christiansen, C., Grauer, A., Kutilek, S., Libanati, C., McClung, M.R., et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26 (2011), 530–537.
72. 72 Chen, P., Satterwhite, J.H., Licata, A.A., Lewiecki, E.M., Sipos, A.A., Misurski, D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005), 962–970.
73. 73 Dobnig, H., Sipos, A., Jiang, Y., Fahrleitner-Pammer, A., Ste-Marie, L.G., Gallagher, J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90 (2005), 3970–3977.
74. 74 Soler-Cataluña, J.J., Martínez-García, M.A., Sánchez, L., Perpina, M., Roman, P., Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med 103 (2009), 692–699.
75. 75 Sen, K., Bonita, R., Global health status: Two steps forward, one step back. Lancet 356 (2000), 577–582.
76. 76 Wijkstra, P.J., van Altena, R., Kraan, J., Otten, V., Postma, D.S., Koëter, G.H., Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 7 (1994), 269–273.
77. 77 Boueri, F.M., Bucher-Bartelson, B.L., Glenn, K.A., Make, B.J., Quality of life measured with a generic instrument (Short Form-36) improves following pulmonary rehabilitation in patients with COPD. Chest 119 (2001), 77–84.
78. 78 Van Manen, J.G., Bindels, P.J., Dekker, F.W., Bottema, B.J., van der Zee, J.S., Ijzermans, C.J., et al. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 56 (2003), 1177–1184.
79. 79 Vigil, L., Güell, M.R., Morante, F., López de Santamaría, E., Sperati, F., Guyatt, G., et al. The validity and sensitivity to change of the Spanish self-administered version of the chronic respiratory questionnaire (CRQ-SAS). Arch Bronconeumol 47 (2011), 343–349.
80. 80 Ferrer, M., Alonso, J., Prieto, L., Plaza, V., Monsó, E., Marrades, R., et al. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: The Spanish example. Eur Respir J 9 (1996), 1160–1166.
81. 81 Hyland, M.E., Singh, S.J., Sodergren, S.C., Morgan, M.P., Development of a shortened version of the Breathing Problems Questionnaire suitable for use in a pulmonary rehabilitation clinic: A purpose-specific, disease-specific questionnaire. Qual Life Res 7 (1998), 227–233.
82. 82 Tu, S.P., McDonell, M.B., Spertus, J.A., Steele, B.G., Fihn, S.D., A new self-administered questionnaire to monitor health-related quality of life in patients with COPD. Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 112 (1997), 614–622.
83. 83 Blanco-Aparicio, M., Vázquez-Rodríguez, I., Verea-Hernando, H., Cultural adaptation into Spanish of the Airways Questionnaire 20, a short health-related quality of life questionnaire for the clinical evaluation of asthma and chronic obstructive pulmonary disease. Arch Bronconeumol 45 (2009), 24–29.
84. 84 Weaver, T.E., Narsavage, G.L., Guilfoyle, M.J., The development and psychometric evaluation of the Pulmonary Functional Status Scale: An instrument to assess functional status in pulmonary disease. J Cardiopulm Rehabil 18 (1998), 105–111.
85. 85 Baecke, J.A., Burema, J., Frijters, J.E., A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36 (1982), 936–942.
86. 86 Garrod, R., Bestall, J.C., Paul, E.A., Wedzicha, J.A., Jones, P.W., Development and validation of a standarized of activity of daily living in patients with severe COPD: The London Chest Activity of Daily Living scale (LCADL). Respir Med 94 (2000), 589–596.
87. 87 Vilaró, J., Gimeno, E., Sánchez-Férez, N., Hernando, C., Díaz, I., Ferrer, M., et al. Daily living activity in chronic obstructive pulmonary disease: Validation of the Spanish version and comparative analysis of 2 questionnaires. Med Clin (Barc) 129 (2007), 326–332.
88. 88 Gea, J., Casadevall, C., Pascual, S., Orozco-Levi, M., Barreiro, E., Respiratory diseases and muscle dysfunction. Expert Rev Resp Med 6 (2012), 75–90.
89. 89 Gea, J., Orozco-Levi, M., Barreiro, E., Ferrer, A., Broquetas, J., Structural and functional changes in the skeletal muscles of COPD patients: The ‘compartments’ theory. Monaldi Arch Chest Dis 56 (2001), 214–224.
90. 90 Costi, S., Crisafulli, E., Anttoni, F.D., Beneventi, C., Fabbri, L.M., Clini, E.M., Effects of unsupoported upper extremity exercise training in patients with COPD: A randomized clinical trial. Chest 136 (2009), 387–395.
91. 91 Pan, L., Guo, Y.Z., Yan, J.H., Zhang, W.X., Sun, J., Li, B.W., Does upper extremity exercise improve dyspnea in patients with COPD? A meta-analysis. Respir Med 106 (2012), 1517–1525.
92. 92 Rodríguez DA, Arbillaga A, Barberan-García A, Ramírez-Sarmiento A, Torralba Y, Vilaró J, et al. Effects of interval and continuous exercise training on autonomic cardiac function in COPD patients. Clin Resp J. 2014. doi: 10.1111/crj.12189.
93. 93 Puhan, M.A., Spaar, A., Frey, M., Turk, A., Brändli, O., Ritscher, D., et al. Early versus late pulmonary rehabilitation in chronic obstructive pulmonary disease patients with acute exacerbations: A randomized trial. Respiration 83 (2012), 499–506.
94. 94 Ambrosino, N., The case for inspiratory muscle training in COPD. Eur Respir J 37 (2011), 233–235.
95. 95 Geddes, E.L., O'Brien, K., Reid, W.D., Brooks, D., Crowe, J., Inspiratory muscle training in adults with chronic obstructive pulmonary disease: An update of a systematic review. Respir Med 102 (2008), 1715–1729.
96. 96 Gosselink, R., de Vos, J., van den Heuvel, S.P., Segers, J., Decramer, M., Kwakkel, G., Impact of inspiratory muscle training in patients with COPD: What is the evidence?. Eur Respir J 37 (2011), 416–425.
97. 97 Ramírez-Sarmiento, A.L., Orozco-Levi, M., Barreiro, E., Méndez, R., Ferrer, A., Broquetas, J., et al. Expiratory muscle endurance in chronic obstructive pulmonary disease. Thorax 57 (2002), 132–136.
98. 98 Levine, S., Kaiser, L., Leferovich, J., Tikunov, B., Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 337 (1997), 1799–1806.
99. 99 Orozco-Levi, M., Gea, J., Lloreta, J.L., Félez, M., Minguella, J., Serrano, S., et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J 13 (1999), 371–378.
100. 100 Orozco-Levi, M., Lloreta, J., Minguella, J., Serrano, S., Broquetas, J., Gea, J., Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001), 1734–1739.
101. 101 Barreiro, E., de la Puente, B., Minguella, J., Corominas, J.M., Serrano, S., Hussain, S.N., et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (2005), 116–124.
102. 102 Marco, E., Ramírez-Sarmiento, A.L., Coloma, A., Sartor, M., Comin-Colet, J., Vila, J., et al. High-intensity vs sham inspiratory muscle training in patients with chronic heart failure: A prospective randomized trial. Eur J Heart Fail 15 (2013), 892–901.
103. 103 Messaggi-Sartor, M., Guillen-Solà, A., Depolo, M., Duarte, E., Rodríguez, D.A., Barrera, M.C., et al. Inspiratory and expiratory muscle training in subacute stroke: A randomized clinical trial. Neurology 85 (2015), 1–9.
104. 104 Bourbeau, J., Nault, D., Dang-Tan, T., Self-management and behaviour modification in COPD. Patient Educ Couns 52 (2004), 271–277.
105. 105 Coll-Fernández, R., Pascual, M.T., Coll, R., Estado actual de la educación para la salud en los programas de rehabilitación respiratoria. Rehabilitacion 45 (2011), 159–165.
106. 106 Monninkhof, E., van der Valk, P., van der Palen, J., van Herwaarden, C., Zielhuis, G., Effects of a comprehensive self-management programme in patients with chronic obstructive pulmonary disease. Eur Respir J 22 (2003), 815–820.
107. 107 Wilson, J.S., ÓNeill, B., Reilly, J., MacMahon, J., Bradley, J.M., Education in pulmonary rehabilitation: The patient's perspective. Arch Phys Med Rehabil 88 (2007), 1704–1709.
108. 108 Bourbeau, J., Julien, M., Maltais, F., Rouleau, M., Beaupré, A., Bégin, R., et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: A disease-specific self-management intervention. Arch Intern Med 163 (2003), 585–591.
109. 109 Zwerink, M., Brusser-Keizer, M., van der Valk, P.D., Zielhuis, G.A., Monninkhof, E.M., van der Palen, J., et al. Self-management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2014, CD002990, 10.1002/14651858.CD002990.
110. 110 Adams, S.G., Smith, P.K., Allan, P.F., Anzueto, A., Pugh, J.A., Cornell, J.E., Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med 167 (2007), 551–561.
111. 111 Wilkinson, T.M., Donaldson, G.C., Hurst, J.R., Seemungal, T.A., Wedzicha, J.A., Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 169 (2004), 1298–1303.
112. 112 Heffner, J.E., Role of pulmonary rehabilitation in palliative care. Respir Care 45 (2000), 1365–1375.
113. 113 Güell, M.R., Cejudo, P., Rodríguez-Trigo, G., Gáldiz, J.B., Casolivé, V., Regueiro, M., et al. Standards for quality care in respiratory rehabilitation in patients with chronic obstructive pulmonary disease. Quality Healthcare Committee. Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Arch Bronconeumol 48 (2012), 396–404.
114. 114 Garrod, R., Lasserson, T., Role of physiotherapy in the management of chronic lung disease: An overview of systematic reviews. Respir Med 101 (2007), 2429–2436.
115. 115 Bhowmik, A., Chachal, K., Austin, G., Chakravorty, I., Improving mucociliary clearance in chronic obstructive pulmonary disease. Respir Med 103 (2009), 496–502.
116. 116 Reddy, R.M., Guntupalli, K.K., Review of ventilatory techniques to optimize mechanical ventilation in acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2 (2007), 441–452.
117. 117 Fink, J.B., Forced expiratory technique, directed cough, and autogenic drainage. Respir Care. 52 (2007), 1210–1223.
118. 118 Martínez, A., Técnicas de fisioterapia respiratoria. Pleguezuelos, E., Miranda, G., Gómez, A., Capellas, L., (eds.) Rehabilitación integral en el paciente con enfermedad pulmonar obstructiva crónica., 2008, Editorial Médica Panamericana, Madrid, 156–164.
119. 119 McCool, F.D., Rosen, M.J., Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 129 (2006), 250S–259S.
120. 120 Walsh, R.L., Occupational therapy as part of a pulmonary rehabilitation program. Occup Ther Health Care 3 (1986), 65–77.
121. 121 Lorenzi, C.M., Cilione, C., Rizzardi, R., Furino, V., Bellantone, T., Lugli, D., et al. Occupational therapy and pulmonary rehabilitation of disabled COPD patients. Respiration 71 (2004), 246–251.
122. 122 Baarends, E.M., Schols, A.M., Slebos, D.J., Mostert, R., Janssen, P.P., Wouters, E.F., Metabolic and ventilatory response pattern to arm elevation in patients with COPD and healthy age-matched subjects. Eur Respir J 8 (1995), 1345–1351.
123. 123 Tangri, S., Woolf, C.R., The breathing pattern in chronic obstructive lung disease during the performance of some common daily activities. Chest 63 (1973), 126–127.
124. 124 Celli, B.R., Rassulo, J., Make, B.J., Dyssynchronous breathing during arm but not leg exercise in patients with chronic airflow obstruction. N Engl J Med 314 (1986), 1485–1490.
125. 125 Martinez, F.J., Vogel, P.D., Dupont, D.N., Stanopoulos, I., Gray, A., Beamis, J.F., Supported arm exercise vs unsupported arm exercise in the rehabilitation of patients with severe chronic airflow obstruction. Chest 103 (1993), 1397–1402.
126. 126 Velloso, M., Jardim, J.R., Study of energy expenditure during activities of daily living using and not using body position recommended by energy conservation techniques in patients with COPD. Chest 130 (2006), 126–132.
127. 127 Jeng, C., Chang, W., Wai, P.M., Chou, C.L., Comparision of oxygen consumption in performing daily activities between patients with chronic obstructive pulmonary disease and healthy population. Heart Lung 32 (2003), 121–130.
128. 128 Coll, R., Prieto, H., Rocha, E., Occupational therapy in chronic obstructive pulmonary disease. Arch Bronconeumol 30 (1994), 101–104 Erratum in: Arch Bronconeumol 1994; 30:257.
129. a ed, 2004, Editorial Masson, Barcelona, 127–138.
130. 130 Coll, R., Vila, M., Técnicas de ahorro de energía. Pleguezuelos, E., Miranda, G., Gómez, A., Capellas, L., (eds.) Rehabilitación integral en el paciente con EPOC., 2008, Editorial Médica Panamericana, Madrid, 165–173.
131. 131 Yohannes, A.M., Willgoss, T.G., Baldwin, R.C., Connolly, M.J., Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: Prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 25 (2010), 1209–1221.
132. 132 Ng, T.P., Niti, M., Tan, W.C., Cao, Z., Ong, K.C., Eng, P., Depressive symptoms and chronic obstructive pulmonary disease: Effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 167 (2007), 60–67.
133. 133 Fan, V.S., Ramsey, S.D., Giardino, N.D., Make, B.J., Emery, C.F., Diaz, P.T., et al., National Emphysema Treatment Trial (NETT) Research Group. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 167 (2007), 2345–2353.
134. 134 Van Manen, J.G., Bindels, P.J.E., Dekker, F.W., Ijzermans, C.J., van der Zee, J.S., Schade, E., Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 57 (2002), 412–416.
135. 135 Eisner, M.D., Blanc, P.D., Yelin, E.H., Katz, P.P., Sánchez, G., Iribarren, C., et al. Influence of anxiety on health outcomes in COPD. Thorax 65 (2010), 229–234.
136. 136 Brenes, G.A., Anxiety and chronic obstructive pulmonary disease: Prevalence, impact, and treatment. Psychosom Med 65 (2003), 963–970.
137. 137 Ng, T.P., Niti, M., Fones, C., Yap, K.B., Tan, W.C., Comorbid association of depression and COPD: A population-based study. Respir Med 103 (2009), 895–901.
138. 138 Maurer, J., Rebbapragada, V., Borson, S., Goldstein, R., Kunik, M.E., Yohannes, A.M., et al. Anxiety and depression in COPD: Current understanding, unanswered questions and research needs. Chest 134 (2008), 43S–56S.
139. 139 Kim, H.F., Kunik, M.E., Molinari, V.A., Hillman, S.L., Lalani, S., Orengo, C.A., et al. Functional impairment in COPD patients: The impact of anxiety and depression. Psychosomatics 41 (2000), 465–471.
140. 140 Coventry, P.A., Hind, D., Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res 63 (2007), 551–565.
141. 141 Paz-Díaz, H., Montes de Oca, M., López, J.M., Celli, B.R., Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 86 (2007), 30–36.
142. 142 Herring, M.P., O'Connor, P.J., Dishman, R.K., The effect of exercise training on anxiety symptoms among patients: A systematic review. Arch Intern Med 170 (2010), 321–331.
143. 143 Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Sys Rev. 2012; CD008427. doi: 10.1002/14651858.CD008427.pub2.
144. 144 Yeh, S.S., DeGuzman, B., Kramer, T., Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122 (2002), 421–428.
145. 145 Make, B., Piquette, C., Kramer, T., Ries, A., Casaburi, R., Oxandrolone increases weight and muscle mass in underweight COPD patients. Chest., 122, 2002, 73S.
146. 146 Schols, A.M., Soeters, P.B., Mostert, R., Pluymers, R.J., Wouters, E.F., Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med. 152 (1995), 1268–1274.
147. 147 Creutzberg, E.C., Wouters, E.F., Mostert, R., Pluymers, R.J., Schols, A.M., A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest. 124 (2003), 1733–1742.
148. 148 Weisberg, J., Wanger, J., Olson, J., Streit, B., Fogarty, C., Martin, T., et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest. 121 (2002), 1070–1078.
149. 149 Pape, G.S., Friedman, M., Underwood, L.E., Clemmons, D.R., The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest. 99 (1991), 1495–1500.
150. 150 Burdet, L., de Muralt, B., Schutz, Y., Pichard, C., Fitting, J.W., Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med. 156 (1997), 1800–1806.
151. 151 Nagaya, N., Itoh, T., Murakami, S., Oya, H., Uematsu, M., Miyatake, K., et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 128 (2005), 1187–1193.
152. 152 Miki, K., Maekura, R., Nagaya, N., Nakazato, M., Kimura, H., Murakami, S., et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: A multicenter, randomized, double-blind, placebo-controlled trial. PLoS One, 7, 2012, e35708.
153. 153 Yeap, S.S., Fauzi, A.R., Kong, N.C., Halim, A.G., Soehardy, Z., Rahimah, I., et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 35 (2008), 2344–2347.
154. 154 Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: A systematic review and cost-utility analysis. Health Technol Assess. 2007; 11:iii-iv, ix-xi, 1-231.
155. 155 Mok, C.C., Ying, K.Y., To, C.H., Ho, L.Y., Yu, K.L., Lee, H.K., et al. Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70 (2011), 778–784.
156. 156 Homik, J., Cranney, A., Shea, B., Tugwell, P., Wells, G., Adachi, R., et al. Bisphosfonates for steroid induced osteoporosis. Cochrane Database Syst Rev, 2, 2000, CD001347.
157. 157 Saag, K.G., Emkey, R., Schnitzer, T.J., Brown, J.P., Hawkins, F., Goemaere, S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis International Study Group. N Engl J Med 339 (1998), 292–299.
158. 158 Stoch, S.A., Saag, K.G., Greenwald, M., Sebba, A.I., Cohen, S., Verbruggen, N., et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 36 (2009), 1705–1714.
159. 159 Eastell, R., Devogelaer, J.P., Peel, N.F., Chines, A.A., Bax, D.E., Sacco-Gibson, N., et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11 (2000), 331–337.
160. 160 Adachi, J.D., Roux, C., Pitt, P.I., Cooper, C., Moniz, C., Dequeker, J., et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 27 (2000), 2424–2431.
161. 161 Ringe, J.D., Dorst, A., Faber, H., Ibach, K., Sorenson, F., Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int 14 (2003), 801–807.
162. 162 Hakala, M., Kröger, H., Valleala, H., Hienonen-Kempas, T., Lehtonen-Veromaa, M., Heikkinen, J., et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: A 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol 41 (2012), 260–266.
163. 163 Reid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373 (2009), 1253–1263.
164. 164 Saag, K.G., Shane, E., Boonen, S., Marin, F., Donley, D.W., Taylor, K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357 (2007), 2028–2039.
165. 165 Saag, K.G., Zanchetta, J.R., Devogelaer, J.P., Adler, R.A., Eastell, R., See, K., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60 (2009), 3346–3355.
166. 166 Dore, R.K., Cohen, S.B., Lane, N.E., Palmer, W., Shergy, W., Zhou, L., et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69 (2010), 872–875.
167. 167 Gea, J., A drug therapy for muscle dysfunction in respiratory disorders. Am J Respir Crit Care Med 185 (2012), 10–11.
168. 168 Doorduin, J., Sinderby, C.A., Beck, J., Stegeman, D.F., van Hees, H.W., van der Hoeven, J.G., et al. The calcium sentitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med 185 (2012), 90–95.
169. 169 Van Hees, H.W., Dekhuijzen, P.N., Heunks, L.M., Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care. 179 (2009), 41–47.
170. 170 Neder, J.A., Sword, D., Ward, S.A., Mackay, E., Cochrane, L.M., Clark, C.J., Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax. 57 (2002), 333–337.
171. 171 Dal Corso, S., Napolis, L., Malaguti, C., Gimenes, A.C., Albuquerque, A., Nogueira, C.R., et al. Skeletal muscle structure and function in response to electrical stimulation in moderately impaired COPD patients. Respir Med 101 (2007), 1236–1243.
172. 172 Vieira, P.J., Chiappa, A.M., Cipriano, G., Umpierre, D., Arena, R., Chiappa, G.R., Neuromuscular electrical stimulation improves clinical and physiological function in COPD patients. Respir Med 108 (2014), 609–620.